Navigation Links
Video: Keppra XR(TM) Approved in the U.S.
Date:9/14/2008

upport program. For more information, contact U.S. UCB Medical Information at 1-866-822-0068 (press 9).

About Epilepsy

Epilepsy is a chronic neurological disorder affecting approximately three million people in the US-making it more common than multiple sclerosis and Parkinson's disease combined. It is caused by abnormal, excessive electrical discharges of the nerve cells, or neurons, in the brain. Epilepsy is characterized by a tendency to have recurrent seizures and defined by two or more unprovoked seizures. There are many different seizure types and epileptic syndromes. Forty percent of patients taking only one AED continue to experience seizures, and approximately 30% of patients taking adjunctive therapy continue to experience seizures. This highlights the ongoing need for the development of new AEDs. For more information about epilepsy, visit http://www.epilepsyfoundation.org, http://www.epilepsy.com, or http://www.epilepsyadvocate.com.

Further information

Andrea Levin, Public Relations Manager, CNS, UCB U.S.

T +1.770.970.8352, Andrea.levin@ucb-group.com

Eimear O'Brien, Global CNS Communications Manager, UCB Group

T +32.2.559.9271, Eimear.OBrien@ucb-group.com

Antje Witte, Vice-President Corporate Communications & Investor Relations, UCB Group

T +32.2.559.9414, Antje.witte@ucb-group.com

About UCB

UCB (Brussels, Belgium, http://www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative medicines with focus on the fields of central nervous system and immunology disorders. Employing around 12,000 people in over 40 countries, UCB achieved revenue of EUR 3.6 billion in 2007. UC
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck
2. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
3. Video: Data From 185,000 ICU Admissions Show Significant Reductions in Mortality:
4. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
5. Video: New, Advanced Therapy Program Helps People Who Stutter Acquire Fluent Speech
6. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
7. Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
8. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
9. US FDA Grants Pediatric Exclusivity for UCBs Keppra(R)
10. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
11. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015 Knowledgent , the ... that explores the potential of big data analytics in ... was developed to help life sciences and healthcare organizations ... to gain critical business insights. , The life sciences ... data driven by patient profiling, compliance and regulatory requirements, ...
(Date:5/21/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... and commercializes proprietary technologies and products for advanced microarray ... the second fiscal quarter ended March 31, 2015. ... advance business with our existing customers and to develop ... CEO of SQI. "The delivery of a fully automated ...
(Date:5/21/2015)... Specialty Pharmacy Times has completed ... to BPA Worldwide as a business publication member. ... data for Specialty Pharmacy Times based on business/distribution, ... a member of BPA Worldwide, Specialty Pharmacy Times ... with the most reliable, unequaled data,” said Chris ...
(Date:5/21/2015)... -- Prima Biomed Ltd. (NASDAQ: PBMD ) a globally ... leader in the development of immunotherapeutic products for the ... data from the Phase II CAN-003 ovarian cancer clinical ... meaningful improvement in Overall Survival ("OS") over standard of ... the group of second remission patients (n=20), the median ...
Breaking Biology Technology:New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8Specialty Pharmacy Times Joins BPA Worldwide 2Correction Continues after Big Move - BrokerBank Securities, Inc. 2
... Even HealthierST. LOUIS, March 31 Recent research reveals ... be beneficial to the diet. And, the majority recognizes ... such as soyfoods even healthier. These findings come from ... - sponsored by the United Soybean Board (USB) ...
... Shire plc (LSE: SHP,NASDAQ: SHPGY ), ... agreement with GlaxoSmithKline plc (NYSE: GSK ... aim of,improving recognition and treatment of ADHD in ... and will more than double the reach and,frequency ...
... U.S. FDA approves Intercell,s first marketed product, a new ... - Commercial product launch in the U.S. planned for ... today announced that the U.S. Food and Drug Administration ... of Japanese Encephalitis (JE). The initial target for use ...
Cached Biology Technology:Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 2Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 3Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 2Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 3Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 4Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 5Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 6Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 2Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 3Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 4
(Date:5/19/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
(Date:5/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... of the executive management team will present at the following ... and Telecom Conference Date: May 18, 2015 Time: ... MA Cowen and Company Technology, Media ... Location: The New York Palace Hotel, New York, ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2
... Society applauds the Government of Argentina for creating two ... with majestic shorelines and abundant wildlife. The new ... Marine Parkwere recently established by the National Congress in ... other marine and coastal species., "We commend the Government ...
... This press release is available in German . ... of human infants was investigated using the prominent ,Stanford Marshmallow Experiment,: ... could either eat it now or wait and receive a second ... delay of several minutes. Interestingly, children that were able to wait ...
... study published online today in Nature Communications , researchers ... Sciences, BGI-Shenzhen, and University of Arizona have completed the genome ... provides new insights for researchers to understand the function and ... Oryza is an idea model system for studying plant ...
Cached Biology News:2 new marine protected areas created on Argentina's southern coasts 22 new marine protected areas created on Argentina's southern coasts 3Doing business with a parrot 2Whole genome sequencing of wild rice reveals the mechanisms underlying oryza genome evolution 2
Request Info...
Request Info...
Recombinant Rat Leptin, Ultra Pure...
Lentigen's manufacturing platform is sufficiently versatile for use in the manufacture of any HIV-based Lentiviral vector. Lentigen will manufacture your LV of choice to the highest possible titer a...
Biology Products: